Trial Design
tumor, Cancer
TUMOR, CANCER
The study was a single-center, prospective, randomized, controlled intervention study with a waiting CG performed at the University Hospital of Wuerzburg, Comprehensive Cancer Center Mainfranken (CCCMF). The Ethics Committee of the University of Würzburg approved the study on 23.04.2021 (Nr. 123/20-me).Cancer patients with diverse tumor entities and acute appointments in institutions of the CCCMF (interdisciplinary oncological therapy outpatient clinic (IOT), various oncological stations of the University Hospital Wuerzburg, and ambulatory psycho-oncology patients) were evaluated by medical records. Eligible patients were contacted on site or by telephone and asked to participate in the study. Afterward, we sent a written patient information sheet and consent form to interested patients contacted by telephone. After signing the consent form and completing the first questionnaire to collect the baseline values (T1), participants were randomly assigned to the IG or CG using a computer-generated list of random numbers. We used a randomization procedure with an allocation ratio of 1:1. A list of participants’ anonymous study numbers was used for external randomization. A scientific member of the Institute of Clinical Epidemiology, University of Wuerzburg, performed randomization (central randomization per envelope), guaranteeing allocation concealment.Then the participants of the IG received the video intervention for 4 weeks, while the participants of the CG had a 4-week waiting period and did not receive any comparable therapy. Both groups completed another questionnaire at the end of this period (T2). After the post-intervention survey, the CG also received a 4-week intervention.Sample size was powered to detect a medium-sized between-group effect (